186 related articles for article (PubMed ID: 37777797)
21. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
22. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
23. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma.
Chen X; Li X; Liu Y; Zhang Z; Zhang X; Huang J; Li H; Li F; Zhang L; Li L; Wu X; Ma W; Sun Z; Yu H; Zhou Z; Feng X; Cui K; Li Z; Zhang H; Zeng Y; Wan X; Chen YH; Zhang M; Zhang Y
Immunotherapy; 2020 Jul; 12(10):681-696. PubMed ID: 32580597
[No Abstract] [Full Text] [Related]
24. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
25. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
Wang YL; Gong Y; Lv Z; Li L; Yuan Y
J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
[No Abstract] [Full Text] [Related]
26. Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy.
Zhu L; Man CW; Harrison RES; Wu Z; Limsakul P; Peng Q; Hashimoto M; Mamaril AP; Xu H; Liu L; Wang Y
ACS Nano; 2024 Mar; 18(11):8531-8545. PubMed ID: 38456901
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment.
Beatty GL; Moon EK
Oncoimmunology; 2014 Nov; 3(11):e970027. PubMed ID: 25941599
[TBL] [Abstract][Full Text] [Related]
28. The efficacy of third generation anti‑HER2 chimeric antigen receptor T cells in combination with PD1 blockade against malignant glioblastoma cells.
Shen L; Li H; Bin S; Li P; Chen J; Gu H; Yuan W
Oncol Rep; 2019 Oct; 42(4):1549-1557. PubMed ID: 31524276
[TBL] [Abstract][Full Text] [Related]
29. A T-cell independent universal cellular therapy strategy through antigen depletion.
Li D; Wang W; Xie S; Ge M; Wang R; Xu Q; Sun Y; Zhu J; Liu H
Theranostics; 2022; 12(3):1148-1160. PubMed ID: 35154479
[No Abstract] [Full Text] [Related]
30. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
31. CD19 chimeric antigen receptor-redirected T cells combined with epidermal growth factor receptor pathway substrate 8 peptide-derived dendritic cell vaccine in leukemia.
Wu M; Zhang L; Zhang H; Ning J; Tu S; He Y; Li Y
Cytotherapy; 2019 Jun; 21(6):659-670. PubMed ID: 31031152
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of CRISPR-based non-viral
Hu Y; Zu C; Zhang M; Wei G; Li W; Fu S; Hong R; Zhou L; Wu W; Cui J; Wang D; Du B; Liu M; Zhang J; Huang H
EClinicalMedicine; 2023 Jun; 60():102010. PubMed ID: 37251628
[TBL] [Abstract][Full Text] [Related]
33. Construction and functional characterization of a fully human anti-CD19 chimeric antigen receptor (huCAR)-expressing primary human T cells.
Mirzaei HR; Jamali A; Jafarzadeh L; Masoumi E; Alishah K; Fallah Mehrjardi K; Emami SAH; Noorbakhsh F; Till BG; Hadjati J
J Cell Physiol; 2019 Jun; 234(6):9207-9215. PubMed ID: 30362586
[TBL] [Abstract][Full Text] [Related]
34. Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy.
Hu SI; Ko MC; Dai YH; Lin HA; Chen LC; Huang KY; Pang TL; Kuo CY; Lin HC
Ann Transl Med; 2020 May; 8(9):584. PubMed ID: 32566611
[TBL] [Abstract][Full Text] [Related]
35. Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma.
Kang L; Zhang J; Li M; Xu N; Qi W; Tan J; Lou X; Yu Z; Sun J; Wang Z; Fu C; Tang X; Dai H; Chen J; Wu D; Yu L
Biomark Res; 2020; 8():14. PubMed ID: 32435496
[TBL] [Abstract][Full Text] [Related]
36. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
37. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
Lee HJ; Hwang SJ; Jeong EH; Chang MH
J Microbiol; 2024 May; ():. PubMed ID: 38700775
[TBL] [Abstract][Full Text] [Related]
38. Bispecific GPC3/PD‑1 CAR‑T cells for the treatment of HCC.
Li D; Qin J; Zhou T; Li Y; Cheng X; Chen Z; Chen J; Zheng WV
Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36896779
[TBL] [Abstract][Full Text] [Related]
39. Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells.
Zhu X; Hu H; Xiao Y; Li Q; Zhong Z; Yang J; Zou P; Cao Y; Meng F; Li W; You Y; Guo AY; Zhu X
Cancer Lett; 2022 Jun; 536():215668. PubMed ID: 35367518
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.
Sawaisorn P; Atjanasuppat K; Uaesoontrachoon K; Rattananon P; Treesuppharat W; Hongeng S; Anurathapan U
PLoS One; 2023; 18(2):e0281735. PubMed ID: 36780428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
